Contrast enhancement and the acute lesion in multiple sclerosis

Neuroimaging Clinics of North America

Volumn 10, Issue 4, 2000, Pages 705-715

  Rovaris, M ^a   Filippi, M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM;

BLOOD BRAIN BARRIER; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

BRAIN; CONTRAST MEDIA; DISEASE PROGRESSION; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE SPECTROSCOPY; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; PROGNOSIS;

EID: 0034447712     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis
2. Serial magnetization transfer imaging in multiple sclerosis lesions
3. Comparison of MR imaging criteria at first presentation to prev conversion to clinically definite multiple sclerosis
4. Interferon beta-1b reduces development of T1 black holes on MRI in secondary progressive multiple sclerosis
5. Sensitivity of enhanced MR in multiple sclerosis: Effects of contrast doses and magnetization transfer contrast
6. Inflammatory CNS demyelination: Histopathologic correlation with in vivo quantitative proton MR spectroscopy
7. Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
8. Multisequence MRI in clinically isolated syndromes and the early development of MS
9. Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology
10. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI
11. Chronic experimental encephalomyelitis produced by bovine proteolipid apoprotein: Immunological studies in rabbits
12. Magnetization transfer ratios of enhancing and non-enhancing lesions in multiple sclerosis
13. Contrast media in MRI
14. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
15. The European/Canadian multicenter, double blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
16. Serial proton magnetic spectroscopy in acute multiple sclerosis lesions
17. Axonal dysfunction and disability in a relapse of multiple sclerosis: Longitudinal study of a patient
18. In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis
19. Two-dimensional 1H NMR studies of membrane changes during the activation of primary T lymphocites
20. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis
21. Lysolecithininduced demyelination in primates: Preliminary in vivo study with MR and magnetization transfer
22. MR imaging including diffusion and magnetization transfer in chronic relapsing experimental encephalomyelitis: Correlation with immunological and pathological data
23. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance
24. Early structural changes in acute MS lesions assessed by serial magnetization transfer studies
25. Comparison of multiple sclerosis clinical subgroups using navigated spin echo diffusion-weighted imaging
26. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis
27. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis
28. Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis
29. A quantitative study of water diffusion in MS lesions and NAWM using echo-planar imaging
30. Magnetization transfer ratios of multiple sclerosis lesions with variable durations of enhancement
31. A one year study of new lesions in multiple sclerosis using monthly gadolinium enhanced MRI: Correlations with changes of T2 and magnetization transfer lesion loads
32. Magnetization transfer changes in the NAWM precede the appearance of enhancing lesions in patient with multiple sclerosis
33. Magnetization transfer ratios in multiple sclerosis lesions enhancing after different dose of gadolinium
34. Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability
35. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis: Implications for clinical trials
36. Interferon β treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology
37. The effect of cladribine on T1 "black hole" changes in progressive MS
38. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS
39. Sensitivity of delayed gadolinium-enhanced MRI in multiple sclerosis
40. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: Longitudinal quantitative analysis
41. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis
42. A serial study of new MS lesions and the white matter from which they arise
43. MR proton spectroscopy in multiple sclerosis
44. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history
45. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers
46. Diffusion imaging of experimental allergic encephalomyelitis
47. Magnetization transfer effect in MR-detected multiple sclerosis lesions: Comparison with gadolinium-enhanced spin-echo images and non-enhanced T1-weighted images
48. Activity revealed in MRI of multiple sclerosis without contrast agent. A preliminary report
49. Predictive value of gadolinium-enhanced MRI for relapse rate and changes in disability/impairment in multiple sclerosis: A meta-analysis
50. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis
51. Heterogeneity of blood-brain barrier changes in multiple sclerosis: An MRI study with gadolinium-DTPA enhancement
52. Gadolinium enhanced MRI disease activity in relapsing-remitting multiple sclerosis
53. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis
54. In vivo magnetic resonance diffusion measurement in the brain of patients with multiple sclerosis
55. Separation of diffusion and per fusion in intravoxel inchoerent motion (WIM) MR imaging
56. Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: Evidence for distinct mechanisms of lesion genesis?
57. MR of wallerian degeneration in the feline visual system: Characterization by magnetization transfer rate with histopathological correlation
58. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis
59. Clinical and magnetic resonance imaging predictors in primary and secondary progressive MS
60. The neuropathology of multiple sclerosis
61. Effect of copolymer-1 on serial gadolinium enhanced MRI in relapsing remitting multiple sclerosis
62. The pathological evolution of multiple sclerosis
63. Using gadolinium-enhanced magnetic resonance imaging to monitor disease activity in multiple sclerosis
64. The cellular origin of lysosomal enzymes in the plaque in multiple sclerosis: A combined histological and biochemical study
65. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis
66. Gadolinfium enhancement increased the sensitivity of MRI in detecting disease activity in MS
67. Effect of interferon β-1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial
68. Serial gadolinium-enhanced magnetic resonance imaging in multiple sclerosis
69. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis
70. In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema
71. Magnetic resonance imaging of antibody-mediated demyelinating experimental allergic encephalomyelitis
72. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging and quantitative lesion volumetry in multiple sclerosis
73. Proton MR spectroscopy of gadolinium-enhanced multiple sclerosis plaques
74. Multiple sclerosis: Histopathological and MR and/or CT correlation in 37 cases at biopsy and 3 cases at autopsy
75. Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination
76. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H
77. Multiple sclerosis lesions: Relationship between MR enhancement pattern and magnetization transfer effect
78. A longitudinal study of magnetization transfer in multiple sclerosis
79. Multiple sclerosis: Remyelination of nascent lesions
80. The fine structure of chronically active multiple sclerosis plaques
81. A comparison of the pathology of primary and secondary progressive multiple sclerosis
82. Therapeutic effect of Mylinax™ (Cladribine) on disease activity and burden in progressive multiple sclerosis. Clinical and MRI outcome of a multicenter, randomized, double-blind, placebo-controlled trial
83. Weekly diffusion-weighted imaging of normal-appearing white matter in MS
84. Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis
85. The value of new magnetic resonance techniques in multiple sclerosis
86. Cumulative effect of a weekly low dose of interferon beta la on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients
87. MRI evolution of new MS lesions enhancing after different doses of gadolinium
88. Intracellular magnetic labeling of lymphocytes for in vivo trafficking studies
89. Magnetic resonance imaging investigation of blood-brain barrier damage in adoptive transfer experimental autoimmune encephalomyelitis
90. Sensitivity of contrast enhanced MRI in multiple sclerosis: Effects of gadolinium dose, magnetisation transfer contrast and delayed imaging
91. Evidence of widespread subtle blood-brain barrier dysfunction associated with progressive MS
92. Method for intracellular magnetic labeling of human mononuclear cells using approved iron contrast agents
93. Clinical worsening in multiple sclerosis is associated with in creased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions
94. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis
95. Statistical power of MRI monitored trials in multiple sclerosis: New data and comparison with previous results
96. Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measure
97. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis
98. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: Relationship to course, gender and age
99. Evidence of interferon β-1a dose response in relapsing-remitting MS. The OWIMS study
100. Patterns of disease activity in multiple sclerosis: Clinical and magnetic resonance imaging study
101. Major differences in the dynamics of primary and secondary progressive multiple sclerosis
102. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration
103. Quantitative MRI in optic neuritis: Correlation with clinical indings and electrophysiology
104. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis
105. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. I. Fundamental concepts
106. Disease activity in multiple sclerosis studied with weekly triple dose magnetic resonance imaging
107. Single dose gadolinium with magnetization transfer contrast versus triple dose gadolinium in detecting enhancing multiple sclerosis lesions
108. Patterns of lesion development in multiple sclerosis: Longitudinal observations with T1-weighted spin-echo and magnetisation transfer MR
109. Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis. Relation to inflammatory activity
110. In vivo noninvasive determination of abnormal water diffusion in the rat brain studied in an animal model for multiple sclerosis by diffusion-weighted NMR imaging
111. Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis
112. Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis
113. Study of relapsing remitting experimental allergic encephalomyelitis SJL mouse model using MION-46L enhanced in vivo MRI: Early histopathological correlation
114. In vivo dynamic MRI tracking of rat T-cells labelled with superparamagnetic iron-oxide particles
115. The pathophysiology of acute optic neuritis